TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12357515

Group type: EXPERIMENTAL
Intervention: 5 Fr guiding catheter
Number of subjects: 171

Group type: COMPARATOR
Intervention: 6 Fr guiding catheter
Number of subjects: 171
Study: 10080213

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost eyedrops once daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0.5% timolol eyedrops twice daily
Number of subjects: 36
Study: 7956634

Group type: EXPERIMENTAL
Intervention: Premixed insulins
Number of subjects: 27

Group type: COMPARATOR
Intervention: Patient-mixed insulins
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pen-type insulin syringes
Number of subjects: 27
Study: 2832328

Group type: EXPERIMENTAL
Intervention: 5-HT (0.1-80 ng/kg/min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ketanserin (5-125 ng/kg/min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ketanserin (125 ng/kg/min) with 5-HT (1 ng/kg/min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ketanserin (50 ng/kg/min) with 5-HT (80 ng/kg/min)
Number of subjects: 20
Study: 30033695

Group type: COMPARATOR
Intervention: Simple Triage and Rapid Treatment (START) system
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Prehospital Advanced Triage Model (META)
Number of subjects: 64
Study: 27329894

Group type: EXPERIMENTAL
Intervention: Passive self-ligating brackets
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 50
Study: 24885637

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Operative treatment
Number of subjects: 0
Study: 22616411

Group type: EXPERIMENTAL
Intervention: Web-based animated pedagogical agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20195215

Group type: EXPERIMENTAL
Intervention: Total disc replacement
Number of subjects: 155

Group type: COMPARATOR
Intervention: Fusion surgery
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Active adverse events related to the study intervention
Number of subjects: 155
Study: 18401285

Group type: EXPERIMENTAL
Intervention: Combination therapy (IT‐Dex + HDPT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: HDPT alone
Number of subjects: 51

Group type: COMPARATOR
Intervention: IT‐Dex alone
Number of subjects: 51
Study: 15844844

Group type: EXPERIMENTAL
Intervention: Acupuncture at the P6 point
Number of subjects: 111

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 111

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 111
Study: 12219782

Group type: EXPERIMENTAL
Intervention: Location-guided screening (LGS) using the AutoPap system with the SlideWizard 2 automated review microscopy station
Number of subjects: 1275

Group type: COMPARATOR
Intervention: Current practice (CP) manual screening
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Location-guided screening (LGS)
Number of subjects: 1275
Study: 10633964

Group type: EXPERIMENTAL
Intervention: Suprapubic catheter (Group A)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Urethral catheter (Group B)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Urethral cleansing (Group C)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 109
Study: 8653235

Group type: EXPERIMENTAL
Intervention: Topical gel preparation of adrenaline (1:2000) and cocaine (4.7%)
Number of subjects: 107

Group type: COMPARATOR
Intervention: 1% plain lignocaine
Number of subjects: 107
Study: 2061364

Group type: EXPERIMENTAL
Intervention: Methylphenidate at 0.15 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methylphenidate at 0.50 mg/kg
Number of subjects: 30
Study: 6669629

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg) for 14 nights
Number of subjects: 5

Group type: COMPARATOR
Intervention: Nitrazepam (5 mg) for 14 nights
Number of subjects: 5
Study: 30369062

Group type: EXPERIMENTAL
Intervention: Bevacizumab administered on-demand every 4 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bevacizumab administered on-demand every 8 weeks
Number of subjects: 120
Study: 28438121

Group type: EXPERIMENTAL
Intervention: Leg elevation (LE)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 150
Study: 27097735

Group type: EXPERIMENTAL
Intervention: 35% carbon dioxide (CO2)‐enriched air mixture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Compressed room air
Number of subjects: 90
Study: 24443923

Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lubricants (used as needed)
Number of subjects: 0
Study: 23200183

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg
Number of subjects: 540

Group type: COMPARATOR
Intervention: Acetaminophen 1000 mg or 650 mg
Number of subjects: 540

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540
Study: 19653745

Group type: EXPERIMENTAL
Intervention: Bimodal stimuli (auditory and vibrotactile)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unimodal auditory stimuli
Number of subjects: 24
Study: 17615999

Group type: EXPERIMENTAL
Intervention: Capsaicin (150 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 14694252

Group type: EXPERIMENTAL
Intervention: Children with SCD
Number of subjects: 64
Study: 11165421

Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 10477

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 10477

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 10477

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 10477

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 10477

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10477
Study: 9829607

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented preterm infant formula from postnatal day 3 to day 30
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 68
Study: 7799495

Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 500000

Group type: EXPERIMENTAL
Intervention: Mastectomy or breast-conserving surgery with radiation therapy
Number of subjects: 500000

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 500000

Group type: EXPERIMENTAL
Intervention: Clinical follow-up without routine testing for metastatic disease
Number of subjects: 500000
Study: 2136324

Group type: EXPERIMENTAL
Intervention: Amiodarone (10 g cumulative dose)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no amiodarone)
Number of subjects: 19
Study: 7391988

Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg over 10 min)
Number of subjects: 24
Study: 28029485

Group type: EXPERIMENTAL
Intervention: Shenfu injection (SFI)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 26496327

Group type: EXPERIMENTAL
Intervention: Genotype-guided therapy (GGT) with peginterferon-alpha/ribavirin (HCV genotype 1: 48 weeks; HCV genotype 2/3: 24 weeks)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Response-guided therapy (RGT) with peginterferon-alpha/ribavirin (HCV genotype 1: 48 or 24 weeks if baseline VL <400,000 IU/mL and RVR; HCV genotype 2/3: 24 or 16 weeks if RVR)
Number of subjects: 203

Group type: COMPARATOR
Intervention: RGT in HCV-1/HBV dually infected patients
Number of subjects: 203
Study: 24397355

Group type: EXPERIMENTAL
Intervention: Dual-hand performance task with affected hand
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Single-hand capacity task
Number of subjects: 15
Study: 22928275

Group type: EXPERIMENTAL
Intervention: Internet-based educational program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 19131153

Group type: EXPERIMENTAL
Intervention: Ormocer-based composite (AD, Admira/Admira Bond, VOCO)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ormocer-based composite (DE, Definite/Etch & Prime 3.0, Dentsply)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bis-GMA-based composite (TC, Tetric-Ceram/Syntac, Ivoclar-Vivadent)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All restorations
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: DE (Definite/Etch & Prime 3.0, Dentsply)
Number of subjects: 32
Study: 17472615

Group type: EXPERIMENTAL
Intervention: Flutrimazole shampoo 1%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ketoconazole shampoo 2%
Number of subjects: 60
Study: 15690558

Group type: EXPERIMENTAL
Intervention: Teacher-led asthma education program in intervention schools
Number of subjects: 4475

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 4475
Study: 11559721

Group type: EXPERIMENTAL
Intervention: Peptides/IFA with IL-12 30 ng/kg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Peptides/IFA without IL-12
Number of subjects: 48
Study: 9834891

Group type: EXPERIMENTAL
Intervention: All-minutes measurement strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Odd-minutes measurement strategy
Number of subjects: 0
Study: 7856296

Group type: EXPERIMENTAL
Intervention: High-titre Edmonston-Zagreb (EZ-H), potency 5.7 log10/dose
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Medium-titre Edmonston-Zagreb (EZ-M), potency 4.7 log10/dose
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: AIK-C, potency 5.5 log10/dose
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Edmonston-Zagreb (EZ-H)
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: AIK-C (after revaccination at age 9.5 months)
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Edmonston-Zagreb (EZ-H) (after revaccination at age 9.5 months)
Number of subjects: 1023
Study: 2543223

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogens for 21 days plus placebo during the last 10 days of each cycle
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 5 mg medrogestone per day for 10 days in conjunction with conjugated equine estrogens
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 22
Study: 1228536

Group type: EXPERIMENTAL
Intervention: Radiation therapy followed by chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 0
Study: 31703586

Group type: EXPERIMENTAL
Intervention: Systematic observation process for population randomization
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Assessment of secondary segments due to high vacancy
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Assessment of tertiary segments
Number of subjects: 400
Study: 29255347

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg) administered once daily for 7 days as monotherapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg) administered once daily for 7 days as monotherapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Coadministration of rosuvastatin and ezetimibe
Number of subjects: 25
Study: 25680984

Group type: EXPERIMENTAL
Intervention: Presence of oligoclonal bands (OCB)
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Number of T2 lesions (2 to 9 lesions vs 0/1 lesions)
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Number of T2 lesions (>9 lesions vs 0/1 lesions)
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Age at CIS
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D3 (25-OH-D) levels
Number of subjects: 1047
Study: 23525316

Group type: EXPERIMENTAL
Intervention: 1 ml of oral 25% glucose solution
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no oral glucose solution)
Number of subjects: 124
Study: 20386134

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CHO supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: PLAC beverage
Number of subjects: 9
Study: 19720913

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 0
Study: 15809781

Group type: EXPERIMENTAL
Intervention: Robot-assisted adrenalectomy (ROBOT) using the da Vinci robotic system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional laparoscopic adrenalectomy (LAP)
Number of subjects: 20
Study: 11719734

Group type: EXPERIMENTAL
Intervention: Low-sodium diet with rofecoxib (25 mg twice daily)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low-sodium diet without rofecoxib
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous furosemide (20 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-sodium diet with furosemide and rofecoxib
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low-sodium diet
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous furosemide
Number of subjects: 6
Study: 8986145

Group type: EXPERIMENTAL
Intervention: Intermediate-dose methotrexate (IDM) plus intrathecal methotrexate (IT MTX)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Cranial radiation (CRT) plus IT MTX
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 596
Study: 8318400

Group type: EXPERIMENTAL
Intervention: Dexamethasone administration added to the antiemetic effect of ondansetron
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ondansetron as a single antiemetic agent
Number of subjects: 42
Study: 3539349

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine 1,600 mg
Number of subjects: 0
Study: 30883486

Group type: EXPERIMENTAL
Intervention: Dynamic IVA training
Number of subjects: 8

Group type: COMPARATOR
Intervention: Static IVA training
Number of subjects: 8
Study: 29114847

Group type: EXPERIMENTAL
Intervention: Intestinal anti-tissue transglutaminase 2 immunoglobulin A (anti-TG2) deposits
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Mucosal deposits in potential CD patients
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Definitive diagnosis of CD after biopsy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Anti-TG2 deposits in normal mucosal architecture
Number of subjects: 62
Study: 27418208

Group type: EXPERIMENTAL
Intervention: CRT + HT
Number of subjects: 101

Group type: COMPARATOR
Intervention: CRT
Number of subjects: 101
Study: 25032115

Group type: EXPERIMENTAL
Intervention: Submucosal resection (SMR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiofrequency turbinate volume reduction (RFTVR)
Number of subjects: 60
Study: 22619887

Group type: EXPERIMENTAL
Intervention: Dysport
Number of subjects: 26

Group type: COMPARATOR
Intervention: Neuronox
Number of subjects: 26
Study: 19804542

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 17852146

Group type: EXPERIMENTAL
Intervention: Estradiol (E2)
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Follicle Stimulating Hormone (FSH)
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone (LH)
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Correlation between E2 and FSH
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Correlation between FSH and LH
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Ethnicity effect on hormone levels
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) effect on hormone levels
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Age effect on hormone levels
Number of subjects: 1020
Study: 16110136

Group type: EXPERIMENTAL
Intervention: GM‐CSF 4 microg/kg/d subcutaneous
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 92
Study: 11875141

Group type: EXPERIMENTAL
Intervention: Early enteral feeding advancement
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Mean gastric residual volume (GRV)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Green gastric residuals (GR)
Number of subjects: 99
Study: 9952063

Group type: EXPERIMENTAL
Intervention: Buprenorphine alone (2 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Buprenorphine with naloxone (2:1 ratio)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Buprenorphine with naloxone (4:1 ratio)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Buprenorphine with naloxone (8:1 ratio)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Morphine alone (15 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7780091

Group type: EXPERIMENTAL
Intervention: High carbohydrate (CHO) diet
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High lipid (LIPID) diet
Number of subjects: 27

Group type: COMPARATOR
Intervention: No food (control)
Number of subjects: 27
Study: 1965290

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1.30% soluble pyrophosphate and 1.50% copolymer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1.30% soluble pyrophosphate without copolymer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice (no anticalculus ingredients)
Number of subjects: 0
Study: 87408

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study: 31621838

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 31320281

Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27230561

Group type: EXPERIMENTAL
Intervention: AdaptivCRT™ (aCRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: echo-optimized
Number of subjects: 60
Study: 26234838

Group type: EXPERIMENTAL
Intervention: EMBOL-X device (group-1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No EMBOL-X device (group-2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 23706949

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 759

Group type: COMPARATOR
Intervention: sham injection
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: sham/0.5 mg ranibizumab after crossover
Number of subjects: 759
Study: 21631446

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clomiphene treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination metformin/clomiphene treatment
Number of subjects: 0
Study: 19306304

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 2875
Study: 16648502

Group type: EXPERIMENTAL
Intervention: Locoregional failure (IBTR and oLRR)
Number of subjects: 2669

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of IBTR
Number of subjects: 2669

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of oLRR
Number of subjects: 2669

Group type: EXPERIMENTAL
Intervention: 5-year DDFS after IBTR
Number of subjects: 2669

Group type: EXPERIMENTAL
Intervention: 5-year DDFS after oLRR
Number of subjects: 2669

Group type: EXPERIMENTAL
Intervention: 5-year OS after IBTR
Number of subjects: 2669

Group type: EXPERIMENTAL
Intervention: 5-year OS after oLRR
Number of subjects: 2669

Group type: EXPERIMENTAL
Intervention: Hazard ratio for mortality associated with IBTR
Number of subjects: 2669

Group type: EXPERIMENTAL
Intervention: Hazard ratio for mortality associated with oLRR
Number of subjects: 2669
Study: 14697110

Group type: EXPERIMENTAL
Intervention: Penn State Children's Hospital Sedation Algorithm (PSCHSA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical controls (before PSCHSA implementation)
Number of subjects: 0
Study: 11370756

Group type: EXPERIMENTAL
Intervention: School-based preventive program with salivary lactobacillus counts as a sugar-motivating tool
Number of subjects: 936

Group type: COMPARATOR
Intervention: Reference group (students from a neighboring district with no dental health-promoting activities)
Number of subjects: 936
Study: 9146515

Group type: EXPERIMENTAL
Intervention: Fixation with PLLA screws (group II)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fixation with titanium screws (group I)
Number of subjects: 20
Study: 8174881

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3230278

Group type: EXPERIMENTAL
Intervention: Methylprednisolone at a dosage of 0.25 mg/kg daily for 6 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29729347

Group type: EXPERIMENTAL
Intervention: P‐COCC
Number of subjects: 151

Group type: COMPARATOR
Intervention: Video alone
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 151
Study: 27312076

Group type: EXPERIMENTAL
Intervention: Standard treatment plus ivabradine (I + SDT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard treatment (SDT)
Number of subjects: 58
Study: 24716466

Group type: EXPERIMENTAL
Intervention: Proactive tobacco treatment intervention (proactive outreach with mailed invitations and telephone calls, access to free NRT and intensive telephone-based behavioral counseling)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2500
Study: 22034522

Group type: EXPERIMENTAL
Intervention: Mind-body-based preventive intervention program (yoga postures, visualization, social exercises, breathing techniques); Duration: 5 weekly sessions.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control condition; No specific intervention details provided.
Number of subjects: 54
Study: 20536952

Group type: EXPERIMENTAL
Intervention: Taspoglutide 20 mg once weekly for 4 weeks, followed by maintenance at 20 mg or titration to 30 mg or 40 mg for an additional 4 weeks.
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Taspoglutide 30 mg once weekly for 4 weeks (after initial 20 mg).
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Taspoglutide 40 mg once weekly for 4 weeks (after initial 20 mg).
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo.
Number of subjects: 129